Patents by Inventor Benny Bang-Andersen

Benny Bang-Andersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210276966
    Abstract: The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.
    Type: Application
    Filed: October 22, 2020
    Publication date: September 9, 2021
    Inventors: Thomas Ruhland, Garrick Paul Smith, Benny Bang-Andersen, Ask Puschl, Ejner Knud Moltzen, Kim Andersen
  • Patent number: 10844029
    Abstract: The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: November 24, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Thomas Ruhland, Garrick Paul Smith, Benny Bang-Andersen, Ask Puschl, Ejner Knud Moltzen, Kim Andersen
  • Publication number: 20200030319
    Abstract: A dose regimes comprising the simultaneous administration of two pharmaceutical compositions, wherein the first pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof for once daily oral administration, and the second pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof which together with said first composition quickly achieves a steady-state plasma level of vortioxetine in said patient which steady-state plasma level is the same as the steady-state vortioxetine plasma level achieved by the administration to said patient of said first composition alone.
    Type: Application
    Filed: March 4, 2019
    Publication date: January 30, 2020
    Inventors: Connie Sanchez Morillo, Karina Krøjer Søby, Benny Bang-Andersen
  • Patent number: 10258617
    Abstract: A dose regimes comprising the simultaneous administration of two pharmaceutical compositions, wherein the first pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof for once daily oral administration, and the second pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof which together with said first composition quickly achieves a steady-state plasma level of vortioxetine in said patient which steady-state plasma level is the same as the steady-state vortioxetine plasma level achieved by the administration to said patient of said first composition alone.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: April 16, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Connie Sanchez Morillo, Karina Krøjer Søby, Benny Bang-Andersen
  • Publication number: 20180153881
    Abstract: A dose regimes comprising the simultaneous administration of two pharmaceutical compositions, wherein the first pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof for once daily oral administration, and the second pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof which together with said first composition quickly achieves a steady-state plasma level of vortioxetine in said patient which steady-state plasma level is the same as the steady-state vortioxetine plasma level achieved by the administration to said patient of said first composition alone.
    Type: Application
    Filed: February 6, 2018
    Publication date: June 7, 2018
    Inventors: Connie Sanchez Morillo, Karina Krøjer Søby, Benny Bang-Andersen
  • Publication number: 20180127389
    Abstract: The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.
    Type: Application
    Filed: June 15, 2017
    Publication date: May 10, 2018
    Inventors: Thomas Ruhland, Garrick Paul Smith, Benny Bang-Andersen, Ask Puschl, Ejner Knud Moltzen, Kim Andersen
  • Patent number: 9913839
    Abstract: A dose regimes comprising the simultaneous administration of two pharmaceutical compositions, wherein the first pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof for once daily oral administration, and the second pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof which together with said first composition quickly achieves a steady-state plasma level of vortioxetine in said patient which steady-state plasma level is the same as the steady-state vortioxetine plasma level achieved by the administration to said patient of said first composition alone.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: March 13, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Connie Sanchez Morillo, Karina Krøjer Søby, Benny Bang-Andersen
  • Publication number: 20180000815
    Abstract: A dose regimes comprising the simultaneous administration of two pharmaceutical compositions, wherein the first pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof for once daily oral administration, and the second pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof which together with said first composition quickly achieves a steady-state plasma level of vortioxetine in said patient which steady-state plasma level is the same as the steady-state vortioxetine plasma level achieved by the administration to said patient of said first composition alone.
    Type: Application
    Filed: September 13, 2017
    Publication date: January 4, 2018
    Inventors: Connie Sanchez Morillo, Karina Krøjer Søby, Benny Bang-Andersen
  • Patent number: 9820984
    Abstract: A dose regimes comprising the simultaneous administration of two pharmaceutical compositions, wherein the first pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof for once daily oral administration, and the second pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof which together with said first composition quickly achieves a steady-state plasma level of vortioxetine in said patient which steady-state plasma level is the same as the steady-state vortioxetine plasma level achieved by the administration to said patient of said first composition alone.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: November 21, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Connie Sanchez Morillo, Karina Krøjer Søby, Benny Bang-Andersen
  • Patent number: 9708280
    Abstract: The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: July 18, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Thomas Ruhland, Garrick Paul Smith, Benny Bang-Andersen, Ask Puschl, Ejner Knud Moltzen, Kim Andersen
  • Publication number: 20170037006
    Abstract: Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine and salts thereof are provided, e.g., for the treatment of neuropathic pain.
    Type: Application
    Filed: March 17, 2016
    Publication date: February 9, 2017
    Inventors: Benny Bang-Andersen, Andre Faldt, Tine Bryan Stensbol, Silke Miller, Heidi Lopez De Diego
  • Publication number: 20160137620
    Abstract: The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.
    Type: Application
    Filed: June 19, 2015
    Publication date: May 19, 2016
    Inventors: Thomas Ruhland, Garrick Paul Smith, Benny Bang-Andersen, Ask Puschl, Ejner Knud Moltzen, Kim Andersen
  • Patent number: 9315459
    Abstract: Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine and salts thereof are provided, e.g., for the treatment of neuropathic pain.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: April 19, 2016
    Assignee: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Andre Faldt, Tine Bryan Stensbol, Silke Miller, Heidi Lopez De Diego
  • Publication number: 20160083359
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Application
    Filed: November 23, 2015
    Publication date: March 24, 2016
    Inventors: Benny Bang-Andersen, André Faldt, Arne Mørk, Heidi Lopez De Diego, René Holm, Tine Bryan Stensbøl, Lone Munch Ringgard, Michael J. Mealy, Michael Harold Rock, Jørgen Brodersen, Morten Jørgensen, Nicholas Moore
  • Patent number: 9125908
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: September 8, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Arne Mork, Tine Bryan Stensbol, Andre Faldt, Rene Holm, Heidi Lopez de Diego
  • Patent number: 9125909
    Abstract: This disclosure relates to 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof in a crystalline form.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: September 8, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Andre Faldt, Arne Mork, Heidi Lopez de Diego, Rene Holm, Tine Bryan Stensbol
  • Patent number: 9125910
    Abstract: This disclosure relates to a method of treating a disease selected from the group consisting of Alzheimer's disease, cognitive impairment, and attention deficit hyperactivity disorder (ADHD). The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: September 8, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Arne Mork, Tine Bryan Stensbol, Andre Faldt
  • Patent number: 9090575
    Abstract: The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: July 28, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Thomas Ruhland, Garrick P. Smith, Benny Bang-Andersen, Ask Puschl, Ejner K. Moltzen, Kim Andersen
  • Publication number: 20150073018
    Abstract: Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine and salts thereof are provided, e.g., for the treatment of neuropathic pain.
    Type: Application
    Filed: November 14, 2014
    Publication date: March 12, 2015
    Inventors: Benny Bang-Andersen, Andre Faldt, Tine Bryan Stensbol, Silke Miller, Heidi Lopez De Diego
  • Patent number: 8969355
    Abstract: This disclosure relates to a method of treating a disease selected from the group consisting of affective disorders, depression, major depressive disorder, anxiety, general anxiety disorder, social anxiety disorder, obsessive compulsive disorder, panic disorder, and panic attacks. The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to a patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: March 3, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Andre Faldt, Rene Holm, Heidi Lopez de Diego